← Leaderboards
Sean A Diehl
University Of Vermont & St Agric College
$2,286,293
Attributed
$5,655,160
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $862.9K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,655,160 · 5
By mechanism
U01$4,391,969 · 1
R21$881,776 · 2
P20$230,643 · 1
F32$150,772 · 1
Top collaborators
- Beth Diane Kirkpatrick7 shared
- Jason W. Botten5 shared
- Sylvia Irene Becker-Dreps4 shared
- Anna Palmer Durbin2 shared
Most similar at University Of Vermont & St Agric College
Same institution · by research overlap
- Beth Diane Kirkpatrick$19,353,029
Others in their field
Top investigators on “B-Lymphocytes”
- Barton F Haynes · Duke University$400,419,833
- Lawrence Corey · Fred Hutchinson Cancer Center$83,920,398
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$83,920,398
- Dan H. Barouch · Fred Hutchinson Cancer Center$66,039,430
- Dennis R. Burton · Scripps Research Institute$63,566,673
- Rafi Ahmed · Emory University$62,743,001
Research focus
B-LymphocytesVaccinesAntibodiesImmunologicsResponseImmunityInfectionExhibitsMediatingNeutralizing AntibodyDengue VirusVaccine DevelopmentViralImmuneVirusExposure ToUnited States National Institutes Of HealthEpitopesVaccinationInsightCd8-Positive T-LymphocytesResearch PersonnelDengue VaccineAntibody-Dependent Enhancement
Grant awards (18)
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$670,995
U01 · FY2025 · AI · contact PI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$635,890
U01 · FY2024 · AI · contact PI
Mucosal immunity to sapovirus in early childhood$193,513
R21 · FY2024 · AI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$608,440
U01 · FY2023 · AI · contact PI
Mucosal immunity to sapovirus in early childhood$246,263
R21 · FY2023 · AI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$608,997
U01 · FY2022 · AI · contact PI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$611,648
U01 · FY2021 · AI · contact PI
Determinants of humoral immunity to norovirus in children$194,575
R21 · FY2021 · AI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$615,445
U01 · FY2020 · AI · contact PI
Determinants of humoral immunity to norovirus in children$247,425
R21 · FY2020 · AI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$640,554
U01 · FY2019 · AI · contact PI
Using Dengue Controlled Human Infection Model to Identify Adaptive Immune Correlates of Protection$230,643
P20 · FY2018 · GM · contact PI
Role of STAT5 and Bcl-xL in human B cell survival$7,000
F32 · FY2008 · AI · contact PI
Role of STAT5 and Bcl-xL in human B cell survival$45,048
F32 · FY2007 · AI · contact PI
Role of STAT5 and Bcl-xL in human B cell survival$7,000
F32 · FY2007 · AI · contact PI
Role of STAT5 and Bcl-xL in human B cell survival$43,428
F32 · FY2006 · AI · contact PI
Role of STAT5 and Bcl-xL in human B cell survival$41,796
F32 · FY2005 · AI
Role of STAT5 and Bcl-xL in human B cell survival$6,500
F32 · FY2005 · AI